Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Context Therapeutics (Nasdaq:CNTX) granted non-qualified stock options totaling 120,000 shares to two new employees as inducement awards under Nasdaq Listing Rule 5635(c)(4).

The options were granted on hire dates (January 1, 2026 and January 12, 2026) with exercise prices equal to the Nasdaq closing prices on those dates ($1.47 and $1.49). Each option has a 10-year term and vests over four years: 25% after one year and the remainder in 36 equal monthly installments, subject to continued service.

News Market Reaction

+6.94%

2 alerts

+6.94% News Effect

+$9M Valuation Impact

$131M Market Cap

0.3x Rel. Volume

On the day this news was published, CNTX gained 6.94%, reflecting a notable positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $9M to the company's valuation, bringing the market cap to $131M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Current share price: $1.52 Inducement options: 120,000 shares Exercise price: $1.47 per share +5 more

8 metrics

Current share price $1.52 Pre-news price for CNTX

Inducement options 120,000 shares Non-qualified stock options to two new employees

Exercise price $1.47 per share Option grant dated January 1, 2026

Exercise price $1.49 per share Option grant dated January 12, 2026

Option term 10 years Term of inducement stock options

Vesting period 4 years 25% at 1 year, then 36 monthly installments

New employees 2 employees Recipients of inducement option grants

ATM capacity $75,000,000 At-the-market program size from 2025-10-24 filings

Market Reality Check

Price: $1.79 Vol: Volume 830,349 is below 2...

low vol

$1.79 Last Close

Volume Volume 830,349 is below 20-day average 1,583,857 (relative volume 0.52x) ahead of this filing-style news. low

Technical Shares at $1.52 are trading above the $0.93 200-day MA, but 24% below the $2.00 52-week high and well above the $0.49 52-week low.

Peers on Argus

CNTX fell 3.18% while close peers were mixed: ACET -4.34%, IGMS -2.31%, IMMX -5....

1 Up

CNTX fell 3.18% while close peers were mixed: ACET -4.34%, IGMS -2.31%, IMMX -5.04%, CNTB +1.37%, STRO +2.99%. Momentum scanner only flagged OKYO at +5.43%, reinforcing a stock-specific move rather than a coordinated biotech rotation.

Historical Context

5 past events · Latest: Nov 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 07	SITC data update	Positive	+4.7%	Early CT-95 and CT-202 data and timelines highlighted at SITC meeting.
Nov 05	Earnings and pipeline	Positive	+1.8%	Narrower loss, strong cash balance, and progress across T cell engager programs.
Oct 28	Investor conferences	Neutral	-4.9%	Announcements of November conference appearances and webcast details.
Oct 06	SITC poster plans	Positive	+10.0%	Planned CT-95 trial-in-progress and CT-202 preclinical poster presentations at SITC.
Oct 03	Inducement option grant	Neutral	+10.0%	Single-employee inducement stock option grant under Nasdaq Rule 5635(c)(4).

Pattern Detected

Recent news has generally been clinical or financing related, with mostly positive price alignment; conference participation once saw a negative divergence.

Recent Company History

Over the last few months, CNTX has reported multiple pipeline and financing milestones. Clinical updates on CTIM‑76, CT‑95, and CT‑202 in Q3 2025 coincided with narrower losses and cash of $76.9M, with modest positive reactions. Conference and SITC poster news around Oct–Nov 2025 also drew generally favorable moves, while one investor-conference announcement on Oct 28 saw a -4.88% reaction. A prior inducement option grant on Oct 1, 2025 was followed by a 10.03% gain, providing a direct historical parallel to today’s hiring-related option awards.

Market Pulse Summary

The stock moved +6.9% in the session following this news. A strong positive reaction aligns with how...

Analysis

The stock moved +6.9% in the session following this news. A strong positive reaction aligns with how CNTX has often traded around administrative and pipeline news. For example, the prior inducement grant on Oct 1, 2025 saw a 10.03% gain, and several clinical updates in late 2025 also produced upside moves. However, investors have an active at-the-market program of up to $75,000,000 in the background, and past reactions have not been uniformly positive, as seen with the -4.88% move after the Oct 28 conference announcement.

Key Terms

non-qualified stock option, nasdaq listing rule 5635(c)(4), t cell engaging bispecific antibodies, exercise price

4 terms

non-qualified stock option financial

"announced that Context has granted non-qualified stock option awards to purchase"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

nasdaq listing rule 5635(c)(4) regulatory

"outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

t cell engaging bispecific antibodies medical

"a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors"

Engineered immune proteins that simultaneously attach to a T cell and a marker on a diseased cell, physically bringing the immune cell and its target together so the T cell can attack and kill the diseased cell. Investors care because these drugs can deliver highly targeted treatments with strong upside if safe and effective, but their clinical results, side‑effect risks and complex manufacturing make trial outcomes and approvals key drivers of a company’s value.

exercise price financial

"with an exercise price equal to the closing price of Context’s common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context.

The stock option awards were granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to the new employees on their hire dates (January 1, 2026 and January 12, 2026) with an exercise price equal to the closing price of Context’s common stock as reported by Nasdaq on the grant date, or the most recent closing price if no sales are made on the applicable grant date ($1.47 and $1.49 per share, respectively).

The stock options have a 10-year term and vest over four years, with one-fourth of the shares underlying the stock option vesting on the first anniversary of the respective grant date and the remainder vesting in thirty-six equal monthly installments thereafter. Vesting of the stock options is subject to continued service with Context through the respective applicable vesting date.

About Context Therapeutics^®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the potential benefits, characteristics, safety and side effect profile of our product candidates, (ii) the likelihood data will support future development of our product candidates, and (iii) the likelihood of obtaining regulatory approval for our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

Investor Relations Contact:
Jennifer Minai-Azary
Context Therapeutics
IR@contexttherapeutics.com

FAQ

What did Context Therapeutics (CNTX) announce on January 16, 2026 about inducement grants?

Context announced non-qualified stock options totaling 120,000 shares granted to two new employees as inducement awards under Nasdaq Listing Rule 5635(c)(4).

What are the exercise prices and grant dates for the CNTX inducement options?

The options were granted on Jan 1, 2026 and Jan 12, 2026 with exercise prices of $1.47 and $1.49, respectively.

What are the term and vesting schedule for the Context Therapeutics (CNTX) inducement options?

Each option has a 10-year term and vests over four years: 25% after one year, then the remainder in 36 equal monthly installments.

Were the CNTX inducement options granted under the company’s 2021 equity plan?

No. The awards were granted outside the 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Do CNTX inducement awards include performance conditions or service-only vesting?

Vesting is subject to continued service through the applicable vesting dates; no performance conditions were disclosed.

How might the 120,000 share inducement grants affect CNTX shareholders in the short term?

The announcement discloses option size, pricing, term, and vesting but does not state immediate dilution metrics or projected shareholder impact.